MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M

MANNKIND CORP

2026-Q1 EPS reported -$0.05 revenue$90,171,000

Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.
Furoscix net sales $15.5M (first full Q1 post-scPharma acquisition); Afrezza $15.3M (+3%).
SG&A surged 116% to $54.1M driven by launch prep for Afrezza pediatric and Furoscix ReadyFlow.
Cash and investments $134M; settled $36.3M convertible notes for $35.5M cash + 569K shares.
Key PDUFA dates: Afrezza pediatric May 29; Furoscix Autoinjector July 26; nintedanib DPI Phase 2 enrollment Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

MANNKIND CORP reported the first quarter of 2026 results: revenue $90,171.

Period: the first quarter of 2026
Revenue: $90,171
Result: reported results

Exact text from the filing

386 3 % Furoscix 15,493 — 15,493 N/A V-Go 3,141 4,086 (945 ) (23 %) Collaborations and services 23,515 29,376 (5,861 ) (20 %) Royalties 32,749 30,005 2,744 9 % Total revenues $ 90,171 $ 78,354 $ 11,817 15 % Total revenues for the first quarter of 2026 increased compared to the same period in the prior year due to higher revenue from royalties and commercial

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0001193125-26-208910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.